News

The Michael J. Fox Foundation (MJFF) is partnering with H1 to enhance the connections between physicians, researchers and patients with Parkinson’s disease. MJFF will use H1’s Trial Landscape platform to identify and communicate with lead researchers and physicians treating Parkinson’s patients, including those in populations typically unrepresented…

A new digital tool called MAP DBS may help improve the efficiency of deep brain stimulation (DBS) for people with Parkinson’s disease, a new study suggests. “We showed that MAP DBS can improve the time spent at the initial DBS programming visit when compared to [standard-of-care] procedures, which has…

An experimental molecule called ONO-2506 was found to reduce the occurrence of abnormal movements — dyskinesia — resulting from early levodopa treatment without compromising levodopa’s therapeutic effects in a rat model of Parkinson’s disease. The mechanisms by which ONO-2506 was able to ease levodopa-induced dyskinesia (LID) appeared…

Several people with Parkinson’s disease were able to improve their ability to walk by using a “wearable cyborg” over their torso, a study reports. The study, “Gait improvement with wearable cyborg HAL trunk unit for parkinsonian patients: five case reports,” was published in Scientific Reports. The work…

A 12-week virtual music therapy program was found to reduce apathy and depression among people with Parkinson’s disease — and to help ease feelings of burden for their caregivers, a new study reported. “Group music therapy is an effective treatment for apathy in PD [Parkinson’s disease] and may improve…

At an upcoming free webinar, hosted by Synapticure, experts will discuss how the chemical trichloroethylene or TCE — a widely-used solvent now well known to have toxic side effects — may be a cause of Parkinson’s disease. The webinar, “TCE: An Invisible Cause of Parkinson’s,” is taking place via…

Anxiety is a common problem for people with Parkinson’s disease and can cause substantial difficulties in patients’ day-to-day lives, a new study based on patient interviews highlights. In some cases, anxiety can be more of a problem than motor symptoms: “I would put up with some of the…

Researchers have identified certain pesticides used in agricultural settings that were linked to Parkinson’s disease risk among people living in California — and that were toxic to nerve cells in laboratory studies. Particularly, a pesticide called trifluralin was a significant driver of nerve cell toxicity, an effect that was…

To help offset the lack of specialty care in Parkinson’s disease, the Parkinson’s Foundation is offering providers who aren’t experts in the progressive neurodegenerative disorder access to the virtual course, “Utilizing Quality Measures to Improve Parkinson’s Care: What Every Neurologist Needs to Know.” The course, which is…

Inhibikase Therapeutics, which is recruiting up to 120 untreated Parkinson’s disease patients across the U.S. to test its oral therapy IkT-148009, announced that its 201 trial program just dosed its first participant. The Phase 2 trial (NCT05424276) is assessing the safety and tolerability of IkT-148009 versus a…